Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries
المؤلفون المشاركون
De Luca, Leonardo
Indolfi, Ciro
Colivicchi, Furio
Massimo Gulizia, Michele
Arca, Marcello
Luigi Temporelli, Pier
Gonzini, Lucio
Venturelli, Vanessa
Morici, Nuccia
Gabrielli, Domenico
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-01-03
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Introduction.
The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known.
Methods.
Using the data from two contemporary, nationwide, prospective, real-world registries of patients with stable coronary artery disease, we sought to describe the lipid lowering therapies prescribed by cardiologists in patients with a prior MI and the resulting eligibility for PCSK9 inhibitors according to the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) and the Italian regulatory agency (Agenzia Italiana del Farmaco; AIFA) criteria.
The study cohort was stratified according to the following low-density lipoprotein cholesterol (LDL-C) levels at the time of enrolment: <70 mg/dl; 70–99 mg/dl and ≥100 mg/dl.
Results.
Among the 3074 post-MI patients with LDL-C levels available, a target level of LDL-C < 70 mg/dl was present in 1186 (38.6%), while 1150 (37.4%) had LDL-C levels ranging from 70 to 99 mg/dl and the remaining 738 (24.0%) an LDL-C ≥ 100 mg/dl.
A statin was prescribed more frequently in post-MI patients with LDL-C levels <70 mg/dl (97.1%) compared to the other LDL-C groups (p<0.0001).
A low dose of statin was prescribed in 9.3%, while a high dose in 61.4% of patients.
Statin plus ezetimibe association therapy was used in less than 18% of cases.
In the overall cohort, 293 (9.8%) and 450 (22.2%) resulted eligible for PCSK9 inhibitors, according to ESC/EAS and AIFA criteria, respectively.
Conclusions.
Post-MI patients are undertreated with conventional lipid lowering therapies.
A minority of post-MI patients would be eligible to PCSK9 inhibitors according to ESC/EAS guidelines and Italian regulatory agency criteria.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Colivicchi, Furio& Massimo Gulizia, Michele& Arca, Marcello& Luigi Temporelli, Pier& Gonzini, Lucio& Venturelli, Vanessa…[et al.]. 2020. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1138596
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Colivicchi, Furio…[et al.]. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1138596
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Colivicchi, Furio& Massimo Gulizia, Michele& Arca, Marcello& Luigi Temporelli, Pier& Gonzini, Lucio& Venturelli, Vanessa…[et al.]. Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. Cardiovascular Therapeutics. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1138596
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1138596
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر